2015 Fiscal Year Final Research Report
Basic and clinical study of new peptide vaccine therapy for patients with oral cancer
| Project/Area Number |
25463115
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Jun-ichi 札幌医科大学, 医学部, 助教 (80404739)
SASAKI Takanori 札幌医科大学, 医学部, 助教 (50548732)
FUJINO Junki 札幌医科大学, 医学部, 研究員 (60620945)
MICHIFURI Yoshitaka 札幌医科大学, 医学部, 研究員 (00457722)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | がんペプチドワクチン / がん抗原 / 口腔がん / サバイビン / がん免疫 |
|---|
| Outline of Final Research Achievements |
We described a sequential clinical trial of SVN-2B peptide vaccine therapy in combination with incomplete Freund’s adjuvant (IFA) and interferon (IFN)-alpha for patients with oral cancer. Results indicated that the combination therapy increased the frequency of peptide specific cytotoxic T lymphocytes (CTLs) more effectively than the peptide alone. This regimen may be useful as a new therapeutic modality.
We isolated oral cancer stem-like cells (CSCs) as aldehyde dehydrogenase 1 bright (ALDH1br) cells. SPRR1B gene was shown to be overexpressed in the ALDH1br cells, indicating that it has a role in cell growth and maintenance by suppression of RASSF4. Furthermore, we established an oral cancer cell line and an autologous CTL line. It was shown that the CTL line recognized autologous tumor cells in an HLA-A24-restricted manner. Precise analyses of the CTL-recognized antigens may provide us with substantial strategies toward developing a more effective cancer peptide vaccine.
|
| Free Research Field |
がん免疫療法
|
